Dipyramole is a pyrimidopyrimidine derivative with vasodilator and antiplatelet properties. The mechanism of action of Dipyramole as an antiplatelet agent involves increased intracellular cyclic adenosine monophosphate (cAMP), which inhibits the platelet shape change. Increased cAMP concentration is due to one or both of two mechanisms: inhibition of phosphodiesterase and blockade of uptake of adenosine (which acts at adenosine A 2 receptors to stimulate platelet adenylyl cyclase and thus increase cAMP).
3. Who can and can't take dipyr >
Dipyramole can be taken by adults to prevent strokes and after heart valve replacement surgery.
It is sometimes prescribed for children to treat a rare illness called Kawasaki disease or prevent blood clots after heart surgery.
Dipyramole isn't suitable for some people. To make sure this medicine is safe for you, tell your doctor if you:
- have had an allergic reaction to Dipyramole or any other medicines in the past
- have angina or other heart problems, or have had a recent heart attack
- have a muscle-weakening disease called myasthenia gravis
- have any bleeding disorders, such as haemophilia or von Willebrand disease
- have low blood pressure
- have migraines
- are trying to get pregnant, are already pregnant or breastfeeding
Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of Dipyr >Table 1 were reported in two heart valve replacement trials comparing Dipyramole tablets and warfarin therapy to either warfarin alone or warfarin and placebo:
On this page
- About Dipyramole
- Key facts
- Who can and can't take Dipyramole
- How and when to take it
- Side effects
- How to cope with side effects
- Pregnancy and breastfeeding
- Cautions with other medicines
- Common questions
Medical Definition of dipyr >
Note: Dipyramole is marketed under the trademark Persantine and when used in combination with aspirin, under the trademark Aggrenox.
Early clinical trials questioned the efficacy of Dipyramole , alone or in combination with ASA, probably because of variability in bioavailability. Recent studies have suggested significant benefit with the new formulation. Addition of modified-release Dipyramole 200 mg twice daily to ASA 25 mg twice daily was associated with a 22% relative risk reduction of major vascular events compared with ASA alone. 45 In a study of ASA (30–325 mg/day) with or without Dipyramole (200 mg twice daily) in patients within 6 months of a transient ischemic attack (TIA) or minor stroke showed 20% reduction of a composite of major vascular events by the combined treatment. 46 The fixed combination of modified-release Dipyramole and low-dose ASA has been approved for stroke prevention.
Important: The information below refers to products available in the United States that contain Dipyramole.
Pharmacokinetics and Metabolism
Following an oral dose of Persantine (Dipyramole) tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of Persantine (Dipyramole) tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyramole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile.